https://orcid.org/0000-0001-5326-1931
Figures & data
Figure 1. BCAT1, IKZF1 And SEPT9 are hypermethylated in gastrointestinal adenocarcinomas. (A) Heatmap showing BCAT1, IKZF1 and SEPT9 methylation (β-value) in gastrointestinal adenocarcinomas (n = 1,093 tumours). (B) Methylation of BCAT1, IKZF1 and SEPT9 in normal tissue versus tumour for (in order from left to right) colorectal adenocarcinoma (n = 45 normal and 396 tumour), gastroesophageal adenocarcinoma (n = 18 normal and 484 tumour), pancreatic adenocarcinoma (n = 10 normal and 177 tumour) and cholangiocarcinoma (n = 9 normal and 36 tumour). ns, no significant difference; *, p < 0.05; ***, p < 0.001 by wilcoxon rank sum test. (C) Gene browser tracks showing the sites detected by the BCAT1, IKZF1 and SEPT9 test (‘amplicon’), corresponding CpG annotation and overlap of differentially methylated regions (coloured bars) called in gastrointestinal adenocarcinoma.
Figure 2. BCAT1, IKZF1 And SEPT9 methylation is more prevalent in gastrointestinal adenocarcinoma when compared to other cancer types. (A) Forest plots comparing methylation of BCAT1, IKZF1 and SEPT9 in different cancers relative to colorectal adenocarcinomas (n = 396 colorectal adenocarcinomas vs. 8601 other tumours). Data analyzed using beta regression. (B) Receiver operating characteristic curves summarizing the sensitivity and discriminatory ability (herein termed specificity) for BCAT1, IKZF1 and SEPT9 methylation in gastrointestinal adenocarcinomas over all other cancers described in (a).
Table 1. Clinicodemographic characteristics and corresponding BCAT1, IKZF1 and SEPT9 methylation in gastrointestinal adenocarcinomas (n = 1093).
Table 2. Predictors of BCAT1, IKZF1 and SEPT9 methylation in gastrointestinal adenocarcinomas.